An exploratory study of PRecision dOsing of moLecular targeted agents based On therapeutic drug monitoriNG

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary) ; Pazopanib (Primary) ; Regorafenib (Primary)
Indications Colorectal cancer; Gastrointestinal stromal tumours; Liver cancer; Renal cell carcinoma; Soft tissue sarcoma
Focus Adverse reactions; Therapeutic Use
Acronyms PROLONG

08 Apr 2021 Results (n=34, data cut off 31 March 2020) evaluating the pharmacokinetics of regorafenib and its active metabolites M-2/M-5 clarifying the relationships between total drug-related exposure and clinical outcomes, published in the Investigational New Drugs.
23 Oct 2020 Results examining the pharmacokinetics of axitinib and the relationship between peak drug concentration (C(max)) and clinical outcomes in real world practice published in the Investigational New Drugs
03 Oct 2020 Results published in the British Journal of Clinical Pharmacology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com